Loading the security overview…
Where the tokens are
| Quarter | Reported | EPS | EPS vs year ago | Revenue | Revenue vs year ago | Consensus EPS |
|---|---|---|---|---|---|---|
| Q2 FY26ended Jun 30, 2026 | Aug 4, 2026 | $13.85 | +18.7% | $651.00M | −0.1% | $1.75 |
| Q1 FY26ended Mar 31, 2026 | May 7, 2026 | −$19.55 | −953.7% | $592.10M | +1.1% | $1.97 |
| Q4 FY25ended Dec 31, 2025 | — | $26.65 | — | $693.20M | +3.9% | — |
| Q3 FY25ended Sep 30, 2025 | — | −$12.70 | −154.4% | $653.00M | +0.5% | — |
| Q2 FY25ended Jun 30, 2025 | — | $11.67 | — | $651.60M | +2.1% | — |
| Q1 FY25ended Mar 31, 2025 | — | $2.29 | −83.0% | $585.40M | −4.2% | — |
| Q4 FY24ended Dec 31, 2024 | — | −$25.62 | −308.8% | $667.50M | −2.0% | — |
| Q3 FY24ended Sep 30, 2024 | — | $23.34 | +541.2% | $649.70M | +2.8% |
Growth compares each quarter with the same fiscal quarter a year earlier, and is left blank where that quarter is missing or its figure was zero or a loss. Consensus is the estimate published before each report. It usually refers to adjusted EPS, so it is shown beside the GAAP figure rather than subtracted from it: the difference would not be a beat or a miss.
Figures describe Bio-Rad Laboratories shares, not any token. As of Aug 4, 2026, from Massive's standardised financials and the earnings calendar.
| — |
| Q2 FY24ended Jun 30, 2024 | — | −$76.26 | — | $638.50M | — | — |
| Q1 FY24ended Mar 31, 2024 | — | $13.45 | — | $610.80M | — | — |
| Q4 FY23ended Dec 31, 2023 | — | $12.27 | — | $681.12M | — | — |
| Q3 FY23ended Sep 30, 2023 | — | $3.64 | — | $632.12M | — | — |